Lysophosphatidic acid as a lipid mediator with multiple biological actions.
about
ATX-LPA1 axis contributes to proliferation of chondrocytes by regulating fibronectin assembly leading to proper cartilage formation.Autotaxin-lysophosphatidic acid-LPA3 signaling at the embryo-epithelial boundary controls decidualization pathwaysLysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters.Cytosolic phospholipase A₂: physiological function and role in disease.Linoleic acid permeabilizes gastric epithelial cells by increasing connexin 43 levels in the cell membrane via a GPR40- and Akt-dependent mechanism.Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cellsAutotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosisLysophosphatidic acid receptors LPA4 and LPA6 differentially promote lymphocyte transmigration across high endothelial venules in lymph nodesComparative analyses of lysophosphatidic acid receptor-mediated signaling.CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation.Different induction of LPA receptors by chemical liver carcinogens regulates cellular functions of liver epithelial WB-F344 cells.The next generation of therapeutics for chronic kidney diseaseLPA signaling through LPA receptors regulates cellular functions of endothelial cells treated with anticancer drugs.Lysophosphatidic acid (LPA) as a pro-fibrotic and pro-oncogenic factor: a pivotal target to improve the radiotherapy therapeutic index.Autotaxin inhibitors: a patent review (2012-2016).Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.Hepatocyte autotaxin expression promotes liver fibrosis and cancer.Group III phospholipase A2 promotes colitis and colorectal cancer.Lipoquality control by phospholipase A2 enzymes.Measurement of Lysophosphatidic Acid and Sphingosine-1-Phosphate by Liquid Chromatography-Coupled Electrospray Ionization Tandem Mass Spectrometry.Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.Lysophosphatidic Acid Protects Against Endotoxin-Induced Acute Kidney Injury.In vivo evidence for possible up-regulating roles of lysophosphatidic acid around fertilization in rats.The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma.Enhanced cellular functions through induction of LPA2 by cisplatin in fibrosarcoma HT1080 cells.Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease.Lysophosphatidic Acid Induces ECM Production via Activation of the Mechanosensitive YAP/TAZ Transcriptional Pathway in Trabecular Meshwork Cells.Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.Autotaxin in Pathophysiology and Pulmonary Fibrosis.Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis'Crystal' Clear? Lysophospholipid Receptor Structure Insights and Controversies
P2860
Q27329465-4AD02B0E-F7DB-4E58-A536-CBD1784098E2Q33903608-9D5DE6CE-69E3-4CCF-9F5C-999380968657Q33922964-C5AA23C5-ABC1-4CFA-BA16-2F7FFAC13208Q35886245-AB8FDC6B-8F3E-45BE-B288-D3F271DF6EFBQ36767766-E034EE96-02FB-4BCA-896B-165B6C9AE9E8Q36771993-CBBB9991-139B-4AD2-96D3-580F13D60ACDQ36913763-0711AD9C-E7F7-4B44-999A-9D7F9D7874A2Q36947317-216404FF-10E7-4D8F-B72E-88776CD7E5FBQ38366897-8E229E52-5B80-47CC-A991-B75D522101D6Q38680111-369453DF-6EBF-4919-BAFB-386BA067A573Q38834862-CB20889F-8780-4EE4-88AC-4E4ABA370CCFQ38845590-39E842A2-6FFC-4F03-8E72-E844A09E3E7FQ38859656-D226772A-F33B-4A45-B182-8561470F1870Q39237720-7A3F15D9-0028-43FC-9FB6-8CCB8B4498E7Q39266426-09DE6AB5-033C-4203-9D93-52FCAB91F02BQ39277013-362F4D4C-DEC0-42EF-99A9-E18D7F321443Q40422363-CF15201A-8435-47E3-BC63-5F4A78E5574AQ42363727-983B35CF-E06E-4F1B-8C2F-833BB68F4E03Q47133692-3E715D3F-BFFA-40F9-97C9-71107065B176Q47808088-081BDEC4-2EAA-49BC-A53B-C2FC92AD10BAQ47817491-E94AC553-1D9F-4318-A7A5-AAEC1A6C892CQ48191486-39FFE869-9F5D-43A2-A8B9-0A62BE0719A5Q48507900-1965D166-4F89-46B9-8607-0CE968FE2567Q48762101-0D054DF9-6395-46E8-8EEF-A5B20BF0445DQ50228598-A6222CE0-9F14-4332-851B-DB4D7637ADB4Q51002375-D60786C8-6737-4937-AF9B-26431FD458E7Q51497691-D48B7829-5283-4655-9B25-C7470C20EC26Q52574347-138689FE-5AAC-466E-92FE-B54022FB4C01Q52689639-4D535D89-48CE-4987-A027-0CAAC6979CE4Q54967305-397FD0C7-D74B-4FFE-A2AB-4F716C76A785Q55420502-08558FF0-5572-462E-898F-692BFB1C21C8Q57067868-F4E54C12-DBF6-4EEB-813A-FF42E28B8C20Q57789232-AE58DB47-5495-46B0-A5E9-96D60651DF79
P2860
Lysophosphatidic acid as a lipid mediator with multiple biological actions.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Lysophosphatidic acid as a lipid mediator with multiple biological actions.
@en
type
label
Lysophosphatidic acid as a lipid mediator with multiple biological actions.
@en
prefLabel
Lysophosphatidic acid as a lipid mediator with multiple biological actions.
@en
P2093
P2860
P356
P1476
Lysophosphatidic acid as a lipid mediator with multiple biological actions.
@en
P2093
Kuniyuki Kano
Shizu Aikawa
Takafumi Hashimoto
P2860
P356
10.1093/JB/MVU077
P50
P577
2014-12-11T00:00:00Z